Department of Pharmacy, Hospital Universitario 12 de Octubre, Avda Cordoba s/n, 28041, Madrid, Spain.
Clin Transl Oncol. 2013 Mar;15(3):219-25. doi: 10.1007/s12094-012-0909-9. Epub 2012 Jul 25.
Hypersensitivity reaction (HSR) to antineoplastic drugs can force doctors to stop treatment and seek other alternatives. These alternatives may be less effective, not as well tolerated and/or more expensive. Another option is to use desensitization protocols that induce a temporary state of tolerance by gradually administering small quantities of the antineoplastic drug until the therapeutic dosage is reached. The aim of this study is to assess the effectiveness of oxaliplatin desensitization protocols.
A retrospective observational study was carried out between January 2006 and May 2011. The inclusion criteria were patients undergoing chemotherapy treatment with oxaliplatin who had developed an HSR to the drug and who were candidates for continuing the treatment using a desensitization protocol. The patients' clinical records were reviewed and variables were gathered relating to the patient, the treatment, the HSR, and the desensitization protocol administered. The data were analysed using version 18.0 of the statistics program SPSS.
A total of 53 desensitization protocols were administered to 21 patients. In 89 % of these cases, no new reactions occurred while the drug was being administered. New reactions of mild severity only occurred in 11 % of cases, and none of these reactions were severe enough for treatment to be stopped. All patients were able to complete the desensitization protocol.
This study confirms that oxaliplatin desensitization protocols are safe and effective and allow patients to continue with the treatment that initially caused an HSR.
抗肿瘤药物的过敏反应(HSR)可能迫使医生停止治疗并寻求其他替代方案。这些替代方案可能效果较差、耐受性较差和/或价格较高。另一种选择是使用脱敏方案,通过逐渐给予小剂量的抗肿瘤药物诱导暂时的耐受状态,直到达到治疗剂量。本研究旨在评估奥沙利铂脱敏方案的有效性。
这是一项在 2006 年 1 月至 2011 年 5 月期间进行的回顾性观察性研究。纳入标准为接受奥沙利铂化疗且对该药物发生 HSR 的患者,这些患者有资格使用脱敏方案继续治疗。回顾患者的临床记录,并收集与患者、治疗、HSR 和给予的脱敏方案相关的变量。使用 SPSS 统计程序版本 18.0 对数据进行分析。
共对 21 名患者进行了 53 次脱敏方案治疗。在这些情况下,89%的患者在给药时没有发生新的反应。只有 11%的患者发生了新的轻度严重程度的反应,没有一个反应严重到需要停止治疗。所有患者均能够完成脱敏方案。
本研究证实奥沙利铂脱敏方案是安全有效的,允许患者继续接受最初引起 HSR 的治疗。